William G. Finn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William G. Finn has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alfred O. Hero
2 shared publicationsKevin M. Carter
Lincoln Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts
2 shared publicationsRaviv Raich
Department of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon
2 shared publicationsAlexandra M. Harrington
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication- Alfred Olivier Hero
University of Michigan
1 shared publication Anjana Menon
University of Michigan Medical School, Ann Arbor, MI, USA
1 shared publication
Latest Publications
- Open Access
- 15 March 2011
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 80B (5) , 282-290
Immunophenotypic signatures of benign and dysplastic granulopoiesis by cytomic profiling
Background: The role of flow cytometry (FCM) in diagnosing myelodysplastic syndromes (MDS) remains controversial, because analysis of myeloid maturation may involve subjective interpretation of sometimes subtle patterns on multiparameter FCM. Methods: Using six‐parameter marker combinations known to be useful in evaluating the myeloid compartment in MDS, we measured objective immunophenotypic differences between non‐neoplastic (n = 25) and dysplastic (n = 17) granulopoiesis using a novel method, called Fisher information nonparametric embedding (FINE), that measures information distances among FCM datasets modeled as individual high‐dimensional probability density functions, rather than as sets of two‐dimensional histograms. Information‐preserving component analysis (IPCA) was used to create information‐optimized “rotated” two‐dimensional histograms for visualizing myelopoietic immunophenotypes for each individual sample. Results: There was a consistent trend of segregation of higher‐grade MDS (RAEB and RCMD) from benign by FINE analysis. This difference was accentuated in cases with morphologic dysgranulopoiesis and in cases with clonal cytogenetic abnormalities. However, lower grades of MDS or cases that lacked morphologic dysgranulopoiesis showed much greater overlap with non‐neoplastic cases. Two cases of reactive left shift were consistently embedded within the higher‐grade MDS group. IPCA yielded two‐dimensional histogram projections for each individual case by relative weighting of measured cellular characteristics, optimized for preserving information distances derived through FINE. Conclusions: Objective analysis by information geometry supports the conclusions of previous studies that there are immunophenotypic differences in the maturation patterns of benign granulopoiesis and high grade MDS, but also reinforces the known pitfalls of overlap between low‐grade MDS and benign granulopoiesis and overlap between reactive granulocytic left shifts and dysplastic granulopoiesis. © 2011 International Clinical Cytometry Society
- 15 March 2011
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 80B (5) , 282-290
Open AccessImmunophenotypic signatures of benign and dysplastic granulopoiesis by cytomic profiling
Background: The role of flow cytometry (FCM) in diagnosing myelodysplastic syndromes (MDS) remains controversial, because analysis of myeloid maturation may involve subjective interpretation of sometimes subtle patterns on multiparameter FCM. Methods: Using six‐parameter marker combinations known to be useful in evaluating the myeloid compartment in MDS, we measured objective immunophenotypic differences between non‐neoplastic (n = 25) and dysplastic (n = 17) granulopoiesis using a novel method, called Fisher information nonparametric embedding (FINE), that measures information distances among FCM datasets modeled as individual high‐dimensional probability density functions, rather than as sets of two‐dimensional histograms. Information‐preserving component analysis (IPCA) was used to create information‐optimized “rotated” two‐dimensional histograms for visualizing myelopoietic immunophenotypes for each individual sample. Results: There was a consistent trend of segregation of higher‐grade MDS (RAEB and RCMD) from benign by FINE analysis. This difference was accentuated in cases with morphologic dysgranulopoiesis and in cases with clonal cytogenetic abnormalities. However, lower grades of MDS or cases that lacked morphologic dysgranulopoiesis showed much greater overlap with non‐neoplastic cases. Two cases of reactive left shift were consistently embedded within the higher‐grade MDS group. IPCA yielded two‐dimensional histogram projections for each individual case by relative weighting of measured cellular characteristics, optimized for preserving information distances derived through FINE. Conclusions: Objective analysis by information geometry supports the conclusions of previous studies that there are immunophenotypic differences in the maturation patterns of benign granulopoiesis and high grade MDS, but also reinforces the known pitfalls of overlap between low‐grade MDS and benign granulopoiesis and overlap between reactive granulocytic left shifts and dysplastic granulopoiesis. © 2011 International Clinical Cytometry Society
- Open Access
Statistical File Matching of Flow Cytometry Data
Flow cytometry is a technology that rapidly measures antigen-based markers associated to cells in a cell population. Although analysis of flow cytometry data has traditionally considered one or two markers at a time, there has been increasing interest in multidimensional analysis. However, flow cytometers are limited in the number of markers they can jointly observe, which is typically a fraction of the number of markers of interest. For this reason, practitioners often perform multiple assays based on different, overlapping combinations of markers. In this paper, we address the challenge of imputing the high dimensional jointly distributed values of marker attributes based on overlapping marginal observations. We show that simple nearest neighbor based imputation can lead to spurious subpopulations in the imputed data, and introduce an alternative approach based on nearest neighbor imputation restricted to a cell's subpopulation. This requires us to perform clustering with missing data, which we address with a mixture model approach and novel EM algorithm. Since mixture model fitting may be ill-posed, we also develop techniques to initialize the EM algorithm using domain knowledge. We demonstrate our approach on real flow cytometry data.
Open AccessStatistical File Matching of Flow Cytometry Data
Flow cytometry is a technology that rapidly measures antigen-based markers associated to cells in a cell population. Although analysis of flow cytometry data has traditionally considered one or two markers at a time, there has been increasing interest in multidimensional analysis. However, flow cytometers are limited in the number of markers they can jointly observe, which is typically a fraction of the number of markers of interest. For this reason, practitioners often perform multiple assays based on different, overlapping combinations of markers. In this paper, we address the challenge of imputing the high dimensional jointly distributed values of marker attributes based on overlapping marginal observations. We show that simple nearest neighbor based imputation can lead to spurious subpopulations in the imputed data, and introduce an alternative approach based on nearest neighbor imputation restricted to a cell's subpopulation. This requires us to perform clustering with missing data, which we address with a mixture model approach and novel EM algorithm. Since mixture model fitting may be ill-posed, we also develop techniques to initialize the EM algorithm using domain knowledge. We demonstrate our approach on real flow cytometry data.
- Open Access
- 18 July 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 76B (1) , 1-7
Analysis of clinical flow cytometric immunophenotyping data by clustering on statistical manifolds: Treating flow cytometry data as high‐dimensional objects
Background: Clinical flow cytometry typically involves the sequential interpretation of two‐dimensional histograms, usually culled from six or more cellular characteristics, following initial selection (gating) of cell populations based on a different subset of these characteristics. We examined the feasibility of instead treating gated n‐parameter clinical flow cytometry data as objects embedded in n‐dimensional space using principles of information geometry via a recently described method known as Fisher Information Non‐parametric Embedding (FINE).Methods: After initial selection of relevant cell populations through an iterative gating strategy, we converted four color (six‐parameter) clinical flow cytometry datasets into six‐dimensional probability density functions, and calculated differences among these distributions using the Kullback‐Leibler divergence (a measurement of relative distributional entropy shown to be an appropriate approximation of Fisher information distance in certain types of statistical manifolds). Neighborhood maps based on Kullback‐Leibler divergences were projected onto two dimensional displays for comparison.Results: These methods resulted in the effective unsupervised clustering of cases of acute lymphoblastic leukemia from cases of expansion of physiologic B‐cell precursors (hematogones) within a set of 54 patient samples.Conclusions: The treatment of flow cytometry datasets as objects embedded in high‐dimensional space (as opposed to sequential two‐dimensional analyses) harbors the potential for use as a decision‐support tool in clinical practice or as a means for context‐based archiving and searching of clinical flow cytometry data based on high‐dimensional distribution patterns contained within stored list mode data. Additional studies will be needed to further test the effectiveness of this approach in clinical practice. © 2008 Clinical Cytometry Society
- 18 July 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 76B (1) , 1-7
Open AccessAnalysis of clinical flow cytometric immunophenotyping data by clustering on statistical manifolds: Treating flow cytometry data as high‐dimensional objects
Background: Clinical flow cytometry typically involves the sequential interpretation of two‐dimensional histograms, usually culled from six or more cellular characteristics, following initial selection (gating) of cell populations based on a different subset of these characteristics. We examined the feasibility of instead treating gated n‐parameter clinical flow cytometry data as objects embedded in n‐dimensional space using principles of information geometry via a recently described method known as Fisher Information Non‐parametric Embedding (FINE).Methods: After initial selection of relevant cell populations through an iterative gating strategy, we converted four color (six‐parameter) clinical flow cytometry datasets into six‐dimensional probability density functions, and calculated differences among these distributions using the Kullback‐Leibler divergence (a measurement of relative distributional entropy shown to be an appropriate approximation of Fisher information distance in certain types of statistical manifolds). Neighborhood maps based on Kullback‐Leibler divergences were projected onto two dimensional displays for comparison.Results: These methods resulted in the effective unsupervised clustering of cases of acute lymphoblastic leukemia from cases of expansion of physiologic B‐cell precursors (hematogones) within a set of 54 patient samples.Conclusions: The treatment of flow cytometry datasets as objects embedded in high‐dimensional space (as opposed to sequential two‐dimensional analyses) harbors the potential for use as a decision‐support tool in clinical practice or as a means for context‐based archiving and searching of clinical flow cytometry data based on high‐dimensional distribution patterns contained within stored list mode data. Additional studies will be needed to further test the effectiveness of this approach in clinical practice. © 2008 Clinical Cytometry Society
- Open Access
Information Preserving Component Analysis: Data Projections for Flow Cytometry Analysis
Flow cytometry is often used to characterize the malignant cells in leukemia and lymphoma patients, traced to the level of the individual cell. Typically, flow cytometric data analysis is performed through a series of 2-dimensional projections onto the axes of the data set. Through the years, clinicians have determined combinations of different fluorescent markers which generate relatively known expression patterns for specific subtypes of leukemia and lymphoma -- cancers of the hematopoietic system. By only viewing a series of 2-dimensional projections, the high-dimensional nature of the data is rarely exploited. In this paper we present a means of determining a low-dimensional projection which maintains the high-dimensional relationships (i.e. information) between differing oncological data sets. By using machine learning techniques, we allow clinicians to visualize data in a low dimension defined by a linear combination of all of the available markers, rather than just 2 at a time. This provides an aid in diagnosing similar forms of cancer, as well as a means for variable selection in exploratory flow cytometric research. We refer to our method as Information Preserving Component Analysis (IPCA).
Open AccessInformation Preserving Component Analysis: Data Projections for Flow Cytometry Analysis
Flow cytometry is often used to characterize the malignant cells in leukemia and lymphoma patients, traced to the level of the individual cell. Typically, flow cytometric data analysis is performed through a series of 2-dimensional projections onto the axes of the data set. Through the years, clinicians have determined combinations of different fluorescent markers which generate relatively known expression patterns for specific subtypes of leukemia and lymphoma -- cancers of the hematopoietic system. By only viewing a series of 2-dimensional projections, the high-dimensional nature of the data is rarely exploited. In this paper we present a means of determining a low-dimensional projection which maintains the high-dimensional relationships (i.e. information) between differing oncological data sets. By using machine learning techniques, we allow clinicians to visualize data in a low dimension defined by a linear combination of all of the available markers, rather than just 2 at a time. This provides an aid in diagnosing similar forms of cancer, as well as a means for variable selection in exploratory flow cytometric research. We refer to our method as Information Preserving Component Analysis (IPCA).
- 1 September 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (4) , 431-436
Diagnostic Pathology and Laboratory Medicine in the Age of “Omics”
- 1 September 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (4) , 431-436
Diagnostic Pathology and Laboratory Medicine in the Age of “Omics”
- Open Access
- 23 February 2006
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 70B (3) , 124-135
Unsupervised immunophenotypic profiling of chronic lymphocytic leukemia
Background: Proteomics and functional genomics have revolutionized approaches to disease classification. Like proteomics, flow cytometry (FCM) assesses concurrent expression of many proteins, with the advantage of using intact cells that may be differentially selected during analysis. However, FCM has generally been used for incremental marker validation or construction of predictive models based on known patterns, rather than as a tool for unsupervised class discovery. We undertook a retrospective analysis of clinical FCM data to assess the feasibility of a cell‐based proteomic approach to FCM by unsupervised cluster analysis.Methods: Multicolor FCM data on peripheral blood (PB) and bone marrow (BM) lymphocytes from 140 consecutive patients with B‐cell chronic lymphoproliferative disorders (LPDs), including 81 chronic lymphocytic leukemia (CLLs), were studied. Expression was normalized for CD19 totals, and recorded for 10 additional B‐cell markers. Data were subjected to hierarchical cluster analysis using complete linkage by Pearson's correlation. Analysis of CLL in PB samples (n = 63) discovered three major clusters. One cluster (14 patients) was skewed toward “atypical” CLL and was characterized by high CD20, CD22, FMC7, and light chain, and low CD23. The remaining two clusters consisted almost entirely (48/49) of cases recorded as typical BCLL. The smaller “typical” BCLL cluster differed from the larger cluster by high CD38 (P = 0.001), low CD20 (P = 0.001), and low CD23 (P = 0.016). These two typical BCLL clusters showed a trend toward a difference in survival (P = 0.1090). Statistically significant cluster stability was demonstrated by expanding the dataset to include BM samples, and by using a method of random sampling with replacement.Conclusions: This study supports the concept that unsupervised immunophenotypic profiling of FCM data can yield reproducible subtypes of lymphoma/chronic leukemia. Expanded studies are warranted in the use of FCM as an unsupervised class discovery tool, akin to other proteomic methods, rather than as a validation tool. © 2006 International Society for Analytical Cytology
- 23 February 2006
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 70B (3) , 124-135
Open AccessUnsupervised immunophenotypic profiling of chronic lymphocytic leukemia
Background: Proteomics and functional genomics have revolutionized approaches to disease classification. Like proteomics, flow cytometry (FCM) assesses concurrent expression of many proteins, with the advantage of using intact cells that may be differentially selected during analysis. However, FCM has generally been used for incremental marker validation or construction of predictive models based on known patterns, rather than as a tool for unsupervised class discovery. We undertook a retrospective analysis of clinical FCM data to assess the feasibility of a cell‐based proteomic approach to FCM by unsupervised cluster analysis.Methods: Multicolor FCM data on peripheral blood (PB) and bone marrow (BM) lymphocytes from 140 consecutive patients with B‐cell chronic lymphoproliferative disorders (LPDs), including 81 chronic lymphocytic leukemia (CLLs), were studied. Expression was normalized for CD19 totals, and recorded for 10 additional B‐cell markers. Data were subjected to hierarchical cluster analysis using complete linkage by Pearson's correlation. Analysis of CLL in PB samples (n = 63) discovered three major clusters. One cluster (14 patients) was skewed toward “atypical” CLL and was characterized by high CD20, CD22, FMC7, and light chain, and low CD23. The remaining two clusters consisted almost entirely (48/49) of cases recorded as typical BCLL. The smaller “typical” BCLL cluster differed from the larger cluster by high CD38 (P = 0.001), low CD20 (P = 0.001), and low CD23 (P = 0.016). These two typical BCLL clusters showed a trend toward a difference in survival (P = 0.1090). Statistically significant cluster stability was demonstrated by expanding the dataset to include BM samples, and by using a method of random sampling with replacement.Conclusions: This study supports the concept that unsupervised immunophenotypic profiling of FCM data can yield reproducible subtypes of lymphoma/chronic leukemia. Expanded studies are warranted in the use of FCM as an unsupervised class discovery tool, akin to other proteomic methods, rather than as a validation tool. © 2006 International Society for Analytical Cytology
- 1 January 2006
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (1) , 121-127
Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma
Trisomy 12 can be seen in many different lymphoid neoplasms. However, many or most mature B-cell leukemias associated with isolated trisomy 12 are reported in the literature as chronic lymphocytic leukemia (CLL) or ‘atypical CLL’. This study reports a case of a mature B-cell leukemia, morphologically and immunophenotypically similar to cases previously published as atypical CLL, in which cytogenetic evaluation revealed an isolated clonal trisomy 12 but no evidence of the mantle cell lymphoma-associated t(11;14)(q13;q32). Further analysis confirmed absence of cyclin-D1 expression. Subsequent lymph node biopsy revealed evidence of large cell transformation of the underlying chronic lymphoproliferative disorder. Gene expression profiling of the initial peripheral blood sample using a cDNA micro-array of ∼10,000 expressed genes revealed a close resemblance between the reported case and 2 cases of known mantle cell lymphoma. When further compared to 7 known ‘typical’ CLL cases, the reported case was classified as mantle cell lymphoma by hierarchical cluster analysis. The case reported here raises interesting questions regarding the nature of cases reported previously as trisomy 12-associated CLL and reinforces the fact that other leukemic lymphoproliferative disorders should be included in the differential diagnosis of such cases. Further study is indicated to elucidate the nature and diversity of disorders previously reported as trisomy 12-associated chronic lymphocytic leukemia.
- 1 January 2006
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (1) , 121-127
Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma
Trisomy 12 can be seen in many different lymphoid neoplasms. However, many or most mature B-cell leukemias associated with isolated trisomy 12 are reported in the literature as chronic lymphocytic leukemia (CLL) or ‘atypical CLL’. This study reports a case of a mature B-cell leukemia, morphologically and immunophenotypically similar to cases previously published as atypical CLL, in which cytogenetic evaluation revealed an isolated clonal trisomy 12 but no evidence of the mantle cell lymphoma-associated t(11;14)(q13;q32). Further analysis confirmed absence of cyclin-D1 expression. Subsequent lymph node biopsy revealed evidence of large cell transformation of the underlying chronic lymphoproliferative disorder. Gene expression profiling of the initial peripheral blood sample using a cDNA micro-array of ∼10,000 expressed genes revealed a close resemblance between the reported case and 2 cases of known mantle cell lymphoma. When further compared to 7 known ‘typical’ CLL cases, the reported case was classified as mantle cell lymphoma by hierarchical cluster analysis. The case reported here raises interesting questions regarding the nature of cases reported previously as trisomy 12-associated CLL and reinforces the fact that other leukemic lymphoproliferative disorders should be included in the differential diagnosis of such cases. Further study is indicated to elucidate the nature and diversity of disorders previously reported as trisomy 12-associated chronic lymphocytic leukemia.
- Open Access
- 1 April 2003
- Published by American Society of Hematology in Blood
- Vol. 101 (7) , 2895
Diagnostic criteria for acute erythroleukemia
- 1 April 2003
- Published by American Society of Hematology in Blood
- Vol. 101 (7) , 2895
Open AccessDiagnostic criteria for acute erythroleukemia